Elan D Louis1, Pam Factor-Litvak2, Monika Michalec3, Wendy Jiang4, Wei Zheng5. 1. GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: EDL2@columbia.edu. 2. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Electronic address: prf1@cumc.columbia.edu. 3. GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA. Electronic address: mg3360@cumc.columbia.edu. 4. Purdue University School of Health Sciences, West Lafayette, IN, USA. Electronic address: jiangw@purdue.edu. 5. Purdue University School of Health Sciences, West Lafayette, IN, USA. Electronic address: wzheng@purdue.edu.
Abstract
BACKGROUND: Harmane (1-methyl-9H-pyrido[3,4-b]indole) (HA) is a potent neurotoxin that has been linked to two neurological diseases, essential tremor and Parkinson's disease. Blood harmane concentrations [HA] are elevated in patients with both diseases. An important question is whether HA is specifically linked with these diseases or alternatively, is a non-specific marker of neurological illness. OBJECTIVES: We assessed whether blood [HA] was elevated in patients with a third neurological disease, dystonia, comparing them to controls. METHODS: Blood [HA] was quantified by high performance liquid chromatography. Subjects comprised 104 dystonia cases and 107 controls. RESULTS: Mean log blood [HA] in dystonia cases was similar to that of controls (0.41±0.51g(-10)/ml vs. 0.38±0.61g(-10)/ml, t=0.42, p=0.68). In unadjusted and adjusted logistic regression analyses, log blood [HA] was not associated with the outcome (diagnosis of dystonia vs. control): odds ratio (OR)unadjusted=1.11, 95% confidence interval (CI)=0.69-1.79, p=0.68; ORadjusted=1.07, 95% CI=0.58-1.97, p=0.84. CONCLUSIONS: In contrast to the elevated blood [HA] that has been reported in patients with essential tremor and Parkinson's disease, our data demonstrate that blood [HA] was similar in patients with dystonia and controls. These findings provide the first support for the notion that an elevated blood [HA] is not a broad feature of neurological disease, and may be a specific feature of certain tremor disorders.
BACKGROUND:Harmane (1-methyl-9H-pyrido[3,4-b]indole) (HA) is a potent neurotoxin that has been linked to two neurological diseases, essential tremor and Parkinson's disease. Blood harmane concentrations [HA] are elevated in patients with both diseases. An important question is whether HA is specifically linked with these diseases or alternatively, is a non-specific marker of neurological illness. OBJECTIVES: We assessed whether blood [HA] was elevated in patients with a third neurological disease, dystonia, comparing them to controls. METHODS: Blood [HA] was quantified by high performance liquid chromatography. Subjects comprised 104 dystonia cases and 107 controls. RESULTS: Mean log blood [HA] in dystonia cases was similar to that of controls (0.41±0.51g(-10)/ml vs. 0.38±0.61g(-10)/ml, t=0.42, p=0.68). In unadjusted and adjusted logistic regression analyses, log blood [HA] was not associated with the outcome (diagnosis of dystonia vs. control): odds ratio (OR)unadjusted=1.11, 95% confidence interval (CI)=0.69-1.79, p=0.68; ORadjusted=1.07, 95% CI=0.58-1.97, p=0.84. CONCLUSIONS: In contrast to the elevated blood [HA] that has been reported in patients with essential tremor and Parkinson's disease, our data demonstrate that blood [HA] was similar in patients with dystonia and controls. These findings provide the first support for the notion that an elevated blood [HA] is not a broad feature of neurological disease, and may be a specific feature of certain tremor disorders.
Authors: Elan D Louis; Julian Benito-León; Sara Moreno-García; Saturio Vega; Juan Pablo Romero; Felix Bermejo-Pareja; Marina Gerbin; Amanda S Viner; Pam Factor-Litvak; Wendy Jiang; Wei Zheng Journal: Neurotoxicology Date: 2012-09-12 Impact factor: 4.294
Authors: Angela Cruz-Hernandez; Zeynep Sena Agim; Paola C Montenegro; George P McCabe; Jean-Christophe Rochet; Jason R Cannon Journal: Neurotoxicology Date: 2018-03 Impact factor: 4.294